Metabolic Imaging in Parkinson Disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27879372.
- Also identified by DOI 10.2967/jnumed.116.183152.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This review focuses on recent human <sup>18</sup>F-FDG PET studies in Parkinson disease. First, an overview is given of the current analytic approaches to metabolic brain imaging data. Next, we discuss how <sup>18</sup>F-FDG PET studies have advanced understanding of the relation between distinct brain regions and associated symptoms in Parkinson disease, including cognitive decline. In addition, the value of <sup>18</sup>F-FDG PET studies in differential diagnosis, identifying prodromal patients, and the evaluation of treatment effects are reviewed. Finally, anticipated developments in the field are addressed.
Medical subject headings
- Brain
- Brain Mapping
- Fluorodeoxyglucose F18
- Glucose
- Parkinson Disease